PEG-MGF
A pegylated mechano growth factor analogue often discussed in performance and recovery circles.
Also referenced as: Pegylated MGF, PEG Mechano Growth Factor
Also appears in: GH axis
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when PEG-MGF crosses your target, drops, or sets a new tracked low—without daily noise.
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary research area: Performance. Also surfaces under GH axis for browsing and discovery.
Pegylated MGF, PEG Mechano Growth Factor
No FDA label signal · 488 trials · 194 PubMed results
Current evidence for PEG-MGF is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
PEG-MGF has no clinical trials that name it and 194 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic. Note: 1 retracted publication in the literature.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What PEG-MGF is
PEG-MGF is a pegylated analogue related to mechano growth factor, a splice variant associated with the IGF-1 system. It is usually framed around muscle repair, hypertrophy interest, or post-training recovery.
Why it matters
It broadens the muscle-growth category beyond IGF-1 LR3 and shows how performance-focused peptide demand often clusters around growth-factor signaling.
Regulatory context
PEG-MGF is not an FDA-approved muscle-building drug in the United States and belongs in the research-market category.
Practical reading note
This is a good example of a peptide where bodybuilding demand can easily outrun evidence quality, so mechanism should not be confused with proof of real-world outcome.